Utrecht (the Netherlands) / Cambridge (USA) — Gilde Healthcare (‘Gilde’), the growth capital firm specialized in healthcare, announces it has sold its minority stake in biopharmaceutical company ProFibrix (Leiden, the Netherlands) to US listed pharmaceutical company The Medicines Company. The transaction represents a total potential value of $ 230 million (approximately € 170 million). ProFibrix has developed a promising blood clotting drug called Fibrocaps which is soon ready for filing for marketing authorization. Gilde has played an active role in the advance of ProFibrix.
The transaction with The Medicines Company consists of two parts. The Medicines Company has agreed to pay $ 90 million for all outstanding equity of ProFibrix en will pay ProFibrix equity holders up to an additional $140 million upon the achievement of agreed-upon US and European regulatory approvals and sales milestones.
Jan Öhrström, CEO ProFibrix:
“Gilde Healthcare has actively supported us with its extensive network, sector knowledge and capital. Furthermore Gilde has played an important part in ProFibrix’ international expansion. With the acquisition by The Medicines Company we will continue to build on this success and remain focused on the development and commercialization of innovative hemostasis products.”
About Gilde Healthcare
Gilde Healthcare (www.gildehealthcare.com) is a European growth capital firm with more than € 450 million capital under management. It invests in health care. Gilde has a proven track record with regard to investments in fast growing companies, turning these companies into mature businesses.
Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start up Facility.
ProFibrix (www.profibrix.com) was founded in 2005 and is headquartered in Leiden, the Netherlands, with a subsidiary in Seattle (USA) since 2008. The company leverages its expertise in fibrinogen technology to develop and bring to market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. Its key product is Fibrocaps, a medical solution for trauma departments in hospitals to clot wounds faster. ProFibrix anticipates filing of Fibrocaps in Europe at the end of this year and in the US at the beginning of next year.
Fibrocaps is a mixture of two essential blood clotting proteins, fibrinogen and thrombin, formulated as a unique dry powder topical product, which is being developed to stop bleeding during or after surgery. Fibrocaps is differentiated from existing liquid fibrin sealants and hemostats: it is ready for immediate use and is stabe at room temperature.
For further information:
Pieter van der Meer
3584 BP Utrecht, The Netherlands
Tel: +31 30 219 2528